Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

43.40 +0.62 (+1.45%)
Streaming Delayed Price Updated: 10:51 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V.

< Previous 1 2 3 4 5 6 Next >
Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx
Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing... 
Via Benzinga
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Exposures COVID-19
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
Exposures COVID-19
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
From QIAGEN N.V.
Via Business Wire
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Digital PCR Technology
From QIAGEN N.V.
Via Business Wire
Qiagen Inks Companion Diagnostic Development, Technology-Licensing Deal With OncXerna
Qiagen NV (NYSE: QGEN) and OncXerna Therapeutics have signed a master agreement to develop a next-generation sequencing (NGS) companion diagnostic for... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
From QIAGEN N.V.
Via Business Wire
Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval
The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE: QGEN) QIAreach SARS CoV-2 Antigen Test. The rapid, portable test can detect... 
Via Benzinga
Exposures COVID-19 Product Safety
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
From QIAGEN N.V.
Via Business Wire
3 Must-Own Healthcare Stocks For Your Portfolio
Healthcare stocks have had a steady run so far this year, with the industry’s growth prospects—based on ongoing digitization to revolutionize and increase demand—motivating investors. Thus, we believe... 
Via Talk Markets
Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line
Qiagen N.V. (NYSE: QGEN) reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in its core product portfolio... 
Via Benzinga
QIAGEN Reports Full Results for Q2 and H1 2021
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Qiagen Stock Drops After Trimming FY21 Earnings Forecast On Weaker COVID-19 Testing Trends
Qiagen NV (NYSE: QGEN) has reported higher-than-expected second-quarter interim earnings but lowered its outlook on weaker demand for COVID-19 tests, sending its... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
From QIAGEN N.V.
Via Business Wire
QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
From QIAGEN N.V.
Via Business Wire
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
From QIAGEN N.V.
Via Business Wire
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
From QIAGEN N.V.
Via Business Wire
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
From Verogen
Via Business Wire
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
From QIAGEN N.V.
Via Business Wire
Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments
Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR... 
Via Benzinga
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.